Home > News > IDT's newsletter provides an insight into the therapeutic use of RNAi
Industry Updates New Products Supplier News Upcoming Events business web

IDT's newsletter provides an insight into the therapeutic use of RNAi

Hits:1671   Date: 8/5/2011
IDT's newsletter provides an insight into the therapeutic use of RNAi
Decoded issue 2 – Featuring an interview with Dr John Rossi
 
Dr John RossiCORALVILLE, IA – (4 August 2011) Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, has released the second issue of its educational and informative newsletter, Decoded. Available to download for free, the second issue of this quarterly newsletter includes a wealth of scientific content, and features an interview with Dr John Rossi (Department of Molecular and Cellular Biology and Beckman Research Institute of City of Hope (Duarte, CA)). With a focus on the biology and applications of eukaryotic small RNAs and their therapeutic use in HIV/AIDS and cancer, Dr Rossi's research provides an insight into the field of RNA interference (RNAi) and its potential uses.
 
In his work Dr Rossi used IDT's DsiRNA to target genes for silencing: "HIV puts its envelope out to the surface of a cell as part of the packaging process when it infects a cell. The envelope is present on the cell membrane before the virus assembles, so we thought that it could act as a receptor and the Dicer-substrate siRNA (DsiRNA) might get internalised via pinocytosis. We developed our own aptamer which was internalised nicely and, when we tagged it with a DsiRNA, we got good delivery, processing of the siRNA in cells, and target knockdown."
 
To benefit from all of this and more on a regular basis, sign up to receive each quarterly issue of Decoded in print or electronically at www.idtdna.com/decoded.
 
About IDT
Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the United States, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to more than 86,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, Calif.; and Leuven, Belgium. For more information visit www.idtdna.com.
 
Integrated DNA Technologies
800-328-2661 (US & Canada)
+1 319-626-8400 (outside US)
productinfo@idtdna.com
www.idtdna.com